Slide 1: Letter to stock exchanges: Investor/Analysts Presentation
AUROBINDO February 9, 2022 To To Listing Department, The Corporate Relations Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED BSE LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Phiroz Jeejeebhoy Towers, MUMBAI ·400 051 25 th floor, Dalal Street, MUMBAI ·400 001 Company Code No. AUROPHA
Slide 2: Aurobindo Pharma Limited Earnings Presentation Q3FY22
Aurobindo Pharma Limited Earnings Presentation Q3FY22
Slide 3: Disclaimer
Disclaimer This presentation is provided for informational purposes only and does not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any interest in or securities of Aurobindo Pharma Limited, nor shall it, or any par
Slide 4: Index
Index Page Q3FY22 Business & Financial Highlights 4 Financial Performance 9 Filings Snapshot 12 Aurobindo Pharma Limited | Earnings Presentation – Q3FY22 3
Slide 5: Q3FY22 Business & Financial Highlights
Q3FY22 Business & Financial Highlights 4
Slide 6: Quarterly Performance (Excluding Natrol)
Quarterly Performance (Excluding Natrol) Revenue (Rs Crore) US Revenue ($ Mn) 6,069 6,065 6,007 5,942 6,002 5,540 5,702 390 401 367 374 393 364 361 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 Q1FY21 Q2FY21 Q3FY21 Q4FY21 Q1FY22 Q2FY22 Q3FY22 EBITDA (Rs Crore) Net Debt to Equity* 1,295 0.08 0.08
Slide 7: Consolidated Financial & Business Highlights (Excluding Natrol) – Q3 FY22
Consolidated Financial & Business Highlights (Excluding Natrol) – Q3 FY22 Revenue from operations at Rs 6,002.2 crore, up 1.0% QoQ, US revenues at US$ 366.9 Million Research & Development (R&D) spend at Rs 393 crore, 6.6% of revenue EBIDTA before Forex and Other income at Rs 1,016.3 crore; EBITDA ma
Slide 8: US Business Performance Highlights (Excluding Natrol)
US Business Performance Highlights (Excluding Natrol) Revenue (Rs Crore) Revenue mix – Q3FY22 2,871 2,968 Orals 2,745 69.5% Total Injectables Injectables* 24.9% 17.2% Branded Oncology** Q3FY21 Q2FY22 Q3FY22 7.7% OTC 5.5% US Formulations • US revenue in Q3FY22 decreased by 4.4% YoY to Rs. 2,745.2 cro
Slide 9: Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights
Europe, ARV, Growth Markets, API Business Revenues & Performance Highlights In Rs Cr Europe Growth Markets ARV API 397 1,671 1,694 396 443 1,662 1,010 781 683 386 145 156 Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 Q3FY21 Q2FY22 Q3FY22 • Europe revenue in Q3FY22 increased • Revenu
Slide 10: Financial Performance
healthier life! 203 Windsor Center Drive
Slide 11: Consolidated Profit & Loss Statement (as reported)
Consolidated Profit & Loss Statement (as reported) Rs Cr Q3FY22 Q3FY21 (%) Chg Q2FY22 (%) Chg Revenue from operations 6,002.2 6,364.9 -6% 5,941.9 1% Gross Profit 3,258.0 3,792.6 -14% 3,436.3 -5% Gross Margin 54.3% 59.6% 57.8% Overheads 2,241.7 2,424.1 -12% 2,249.6 0% EBITDA (before forex and other i
Slide 12: Debt profile
Debt profile Debt as on (Rs Cr) Mar-19 Mar-20 Mar-21 Sep-21 Dec-21 Fx Loan US$ Mn Closing Rate1 US$ = INR 69.15 75.66 73.11 74.23 74.33 Fx Loan restated in INR 6,959.0 5,549.2 4.928.8 4,391.3 3,711.1 1006 732 674 592 499 Rupee Loan 8.1 16.9 43.6 (0.1) 1.2 Gross Debt 6,967.1 5,566.1 4,972.4 4,391.2 3
Slide 13: Filing Status
healthier life! 203 Windsor Center Drive
Slide 14: US Filings Snapshot as on 31st December 2021
US Filings Snapshot as on 31st December 2021 ANDA Filings Addressable 494 Therapy ANDAs Market Size 378 (US$ Bn) Non - Injectables 116 Injectables CNS 131 28.27 195 163 62 CVS 105 34.15 30 ARV** 40 1.63 Final Tentative Under Gastroenterological 37 3.56 Approved Awaiting final Approval Approval Revie
Slide 15: Global regulatory filing details
Global regulatory filing details As at As at As at As at As at As at As at As at Category Approvals Mar 15 Mar 16 Mar 17 Mar 18 Mar 19 Mar 20 Mar 21 Dec 21 Formulations US* 376 398 429 478 541 586 639 719 524 (FA: 494, TA:30) 2,873 Dossiers (335 Europe** 1,756 2,224 2,521 2,848 3,003 3,214 3,374 3,5
Slide 16: Thank You
Thank You For more information, contact Investor Relations | Corporate Communications +91 40 6672 5401 ir@aurobindo.com www.aurobindo.com